Развитие SARS-CoV-2-атипичного тиреоидита у пациента с тяжелым течением COVID-19

Новая коронавирусная инфекция SARS-CoV-2 (COVID-19) вошла в историю как одна из самых смертоносных пандемий человечества. С момента первых сообщений о заражении SARS-CoV-2 появилось множество данных относительно особенностей патогенеза COVID-19 и влияния вируса на различные органы и ткани. Известно, что SARS-CoV-2 может вызывать как легочное, так и системное воспаление, обуславливающее полиорганную дисфункцию. Кроме того, с нчала пандемии продолжают появляться сообщения о взаимосвязи COVID-19 и нарушениями функции щитовидной железы (ЩЖ). В многочисленных исследованиях было продемонстрировано, что ЩЖ и вся ось «гипоталамус-гипофиз-ЩЖ» могут быть значимыми мишенями для патогенного воздействия SARS-CoV-2.
Классическими нарушениями функции ЩЖ при инфекционных заболеваниях, описанными также и при COVID-19, считают подострый тиреоидит и вторичный гипотиреоз. Особый интерес вызывает развитие на фоне COVID-19 атипичного тиреоидита-SARS-CoV-2 – состояния, впервые зарегистрированного во время COVID-19, ассоциированного с грозными сердечно-сосудистыми осложнениями и высокой летальностью пациентов с COVID-19, не встречавшемся ранее при других вирусных инфекциях.
В данной статье описывается клинический случай развития атипичного тиреоидита- SARS-CoV-2 у пациента с двусторонней вирусной пневмонией в остром периоде COVID-19.

1. World Health Organization. COVID-19 Weekly Epidemiological Update. World Heal Organ. 2022;(August):1-33. https://www.who.int/publications/m/item/covid-19-weekly-epidemiological-update

2. Lania A, Sandri MT, Cellini M, Mirani M, Lavezzi E, Mazziotti G. Thyrotoxicosis in patients with COVID-19: The THYRCOV study. Eur J Endocrinol. 2020;183(4):381-387. doi:10.1530/EJE-20-0335

3. Scappaticcio L, Pitoia F, Esposito K, Piccardo A, Trimboli P. Impact of COVID-19 on the thyroid gland: an update. Rev Endocr Metab Disord. 2021;22(4):803-815. doi:10.1007/s11154-020-09615-z

4. Ruggeri RM, Campennì A, Deandreis D, et al. SARS-COV-2-related immune-inflammatory thyroid disorders: facts and perspectives. Expert Rev Clin Immunol. 2021;17(7):737-759. doi:10.1080/1744666X.2021.1932467

5. Tanda SIFDML. SARS ‑ CoV ‑ 2 : a potential trigger for subacute thyroiditis ? Insights from a case report. J Endocrinol Invest. 2020;43(8):1171-1172. doi:10.1007/s40618-020-01312-7

6. Des M, Juan JS, Florencio MQ V, Joven MH. Case Report SUBACUTE THYROIDITIS IN A PATIENT WITH CORONAVIRUS DISEASE 2019. 2020;6(6):361-364. doi:10.4158/ACCR-2020-0524

7. Haft JW, Atluri P, Ailawadi G, et al. Adult Cardiac Surgery During the COVID-19 Pandemic: A Tiered Patient Triage Guidance Statement. Ann Thorac Surg. 2020;110(2):697-700. doi:10.1016/j.athoracsur.2020.04.003

8. Ziegler CGK, Allon SJ, Nyquist SK, et al. SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues. Cell. 2020;181(5):1016-1035.e19. doi:10.1016/j.cell.2020.04.035

9. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271-280.e8. doi:10.1016/j.cell.2020.02.052

10. Naguib R. Potential relationships between COVID-19 and the thyroid gland: an update. J Int Med Res. 2022;50(2). doi:10.1177/03000605221082898

11. Trovato M, Ruggeri RM, Sciacchitano S, et al. Serum interleukin-6 levels are increased in HIV-infected patients that develop autoimmune disease during long-term follow-up. Immunobiology. 2018;223(3):264-268. doi:10.1016/j.imbio.2017.10.039

12. Kristensen B, Hegedüs L, Madsen HO, Smith TJ, Nielsen CH. Altered balance between self-reactive T helper (Th)17 cells and Th10 cells and between full-length forkhead box protein 3 (FoxP3) and FoxP3 splice variants in Hashimoto’s thyroiditis. Clin Exp Immunol. 2015;180(1):58-69. doi:10.1111/cei.12557

13. Czarnywojtek A, Ochmańska A, Zgorzalewicz-Stachowiak M, et al. Influence of SARS-CoV-2 infection on thyroid gland function: The current knowledge. Adv Clin Exp Med. 2021;30(7):747-755. doi:10.17219/acem/139622

14. Chen M, Zhou W, Xu W. Thyroid Function Analysis in 50 Patients with COVID-19: A Retrospective Study. Thyroid. 2021;31(1):8-11. doi:10.1089/thy.2020.0363

15. de Vries EM, Fliers E, Boelen A. The molecular basis of the nonthyroidal illness syndrome. J Endocrinol. 2015;225(3):R67-R81. doi:10.1530/JOE-15-0133

16. Lei YMK, Lekha N, Alegre ML. Endocrine and metabolic considerations in critically ill patients. Clin Res Hepatol Gastroenterol. 2015;39(1):9-19. doi:10.1016/S2213-8587(15)00225-9.Endocrine

17. Van Den Berghe G. Non-thyroidal illness in the ICU: A syndrome with different faces. Thyroid. 2014;24(10):1456-1465. doi:10.1089/thy.2014.0201

18. Christensen J, O’Callaghan K, Sinclair H, et al. Risk factors, treatment and outcomes of subacute thyroiditis secondary to COVID-19: a systematic review. Intern Med J. 2022;52(4):522-529. doi:10.1111/imj.15432

19. Rossetti CL, Cazarin J, Hecht F, et al. COVID-19 and thyroid function: What do we know so far? Front Endocrinol (Lausanne). 2022;13(December). doi:10.3389/fendo.2022.1041676

20. Ghareebian H, Mariash C. COVID-19-Induced Graves’ Disease. Cureus. 2022;8(2):19-21. doi:10.7759/cureus.22260

21. Muller I, Muller I, Daturi A, et al. Long-term outcome of thyroid abnormalities in patients with severe Covid-19. Published online 2023.

22. Pal R, Joshi A, Bhadada SK, Banerjee M, Vaikkakara S, Mukhopadhyay S. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- 19 . The COVID-19 resource centre is hosted on Elsevier Connect , the company ’ s public news and information . 2020;(January).

23. Mattar SAM, Koh SJQ, Rama Chandran S, Cherng BPZ. Subacute thyroiditis associated with COVID-19. BMJ Case Rep. 2020;13(8):3-6. doi:10.1136/bcr-2020-237336

24. Hariyanto TI, Putri C, Situmeang RF V., Kurniawan A. Dementia is Associated with Severe Coronavirus Disease 2019 (COVID-19) Infection. Am J Med Sci. 2021;361(3):394-395. doi:10.1016/j.amjms.2020.10.026

25. Cho J, Afolabi B. Ventricular fibrillation associated with Graves’ disease and amiodarone induced thyrotoxicosis. Cardiovasc Endocrinol Metab. 2019;8(4):119-124. doi:10.1097/XCE.0000000000000184

26. Shrestha NK, Burke PC, Nowacki AS, Terpeluk P, Gordon SM. ce pt e d an us cr ip t Ac ce pt e us cr t. 2022;6151:1-22.

27. Lisco G, De Tullio A, Jirillo E, et al. Thyroid and COVID-19: a review on pathophysiological, clinical and organizational aspects. J Endocrinol Invest. 2021;44(9):1801-1814. doi:10.1007/s40618-021-01554-z

28. Sastry S, Cuomo F, Muthusamy J. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- 19 . The COVID-19 resource centre is hosted on Elsevier Connect , the company ’ s public news and information . 2020;(January).

29. Lodigiani C, Iapichino G, Carenzo L, Cecconi M, Ferrazzi P. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- 19 . The COVID-19 resource centre is hosted on Elsevier Connect , the company ’ s public news and information . 2020;(January).

30. Davis PJ, Mousa SA, Schechter GP. New Interfaces of Thyroid Hormone Actions With Blood Coagulation and Thrombosis. Clin Appl Thromb. 2018;24(7):1014-1019. doi:10.1177/1076029618774150

31. Ordookhani A, Burman KD. Hemostasis in overt and subclinical hyperthyroidism. Int J Endocrinol Metab. 2017;15(3). doi:10.5812/ijem.44157

32. Li M, Li L, Zhang Y, Wang X. An Investigation of the Expression of 2019 Novel Coronavirus Cell Receptor Gene ACE2 in a Wide Variety of Human Tissues. Infect Dis Poverty. 2020;9(1)(45):1-7. https://doi.org/

33. Muller, I., Daturi, A., Varallo, M., Re, T. E., Dazzi, D., Maioli, S., Crivicich, E., Di Marco, F., Longari, V., Dazzi, B., Castellani, M., Mantovani, G., Arosio, M., & Salvi, M. (2023). Long-term outcome of thyroid abnormalities in patients with severe Covid-19, European Thyroid Journal, 12(2), e220200. Retrieved Mar 20, 2023, from https://doi.org/10.1530/ETJ-22-0200

34. Mateu-Salat M, Urgell E, Chico A. SARS-COV-2 as a trigger for autoimmune disease: report of two cases of Graves’ disease after COVID-19. J Endocrinol Invest. 2020;43(10):1527-1528. doi:10.1007/s40618-020-01366-7

35. Pawlikowski M, Winczyk K. Endocrine and metabolic aspects of COVID-19. Endokrynol Pol. 2021;72(3):256-260. doi:10.5603/EP.A2021.0023

36. Boaventura P, Macedo S, Ribeiro F, Jaconiano S, Soares P. Post-COVID-19 Condition : Where Are We Now ? Published online 2022:1-14.

37. Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016;26(10):1343-1421. doi:10.1089/thy.2016.0229

38. Martins JRM, Villagelin DGP, Carvalho GA, et al. Management of thyroid disorders during the COVID-19 outbreak: a position statement from the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism (SBEM). Arch Endocrinol Metab. 2021;65(3):368-375. doi:10.20945/2359-3997000000352

39. Organización Mundial de la Salud (OMS). Clinical guidance of severe SARS when Covid19 disease is suspected. Organ Mund la Salud. 2020;1(December 2019):1-19.

40. Bartalena L, Chiovato L, Marcocci C, Vitti P, Piantanida E, Tanda ML. Management of Graves’ hyperthyroidism and orbitopathy in time of COVID-19 pandemic. J Endocrinol Invest. 2020;43(8):1149-1151. doi:10.1007/s40618-020-01293-7